DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this compound. Additional details are available on the delafloxacin meglumine profile page.
Generic Entry Opportunity Date for 208611
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208611
Suppliers and Packaging for NDA: 208611
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||POWDER;INTRAVENOUS||Strength||EQ 300MG BASE/VIAL|
|Approval Date:||Jun 19, 2017||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jun 19, 2027|
|Regulatory Exclusivity Use:||GENERATING ANTIBIOTIC INCENTIVES NOW|
|Regulatory Exclusivity Expiration:||Jun 19, 2022|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Mar 13, 2029||Product Flag?||Y||Substance Flag?||Delist Request?|
Complete Access Available with Subscription